Cardiff Oncology, Inc. (CRDF): EBITDA
-$48.60M
Year ended 2025-12-31
-$41.91M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$48.60M | n/m | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | -$48.25M | n/m | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | -$45.01M | n/m | 2025-02-27, From 2023-01-01 |
| 2022-12-31 | -$39.67M | n/m | 2024-02-29, From 2022-01-01 |
| 2021-12-31 | -$28.40M | n/m | 2023-03-02, From 2021-01-01 |
| 2020-12-31 | -$18.62M | n/m | 2022-02-24, From 2020-01-01 |
| 2019-12-31 | -$16.18M | n/m | 2021-02-25, From 2019-01-01 |
| 2018-12-31 | -$16.19M | n/m | 2020-02-27, From 2018-01-01 |
| 2017-12-31 | -$24.35M | n/m | 2019-03-06, From 2017-01-01 |
| 2016-12-31 | -$39.08M | n/m | 2018-02-26, From 2016-01-01 |
| 2015-12-31 | -$24.89M | n/m | 2017-03-15, From 2015-01-01 |
| 2014-12-31 | -$14.71M | n/m | 2017-03-15, From 2014-01-01 |
| 2013-12-31 | -$10.56M | n/m | 2016-03-10, From 2013-01-01 |
| 2012-12-31 | -$4.81M | n/m | 2015-03-12, From 2012-01-01 |
| 2011-12-31 | -$2.97M | n/a | 2014-03-17, From 2011-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | -$48.60M | n/m |
| ImageneBio, Inc. (IMA) | 2025-12-31 | -$48.05M | n/m |
| Prokidney Corp. (PROK) | 2025-12-31 | -$158.43M | n/m |
| Pluri Inc. (PLUR) | 2026-06-30 | -$24.43M | n/m |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | -$132.54M | n/m |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | -$6.12M | n/m |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | -$66.94M | n/m |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | -$76.96M | n/m |
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | -$11.27M | n/m |
Compare CRDF, IMA, PROK, PLUR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗